Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jessica Merrill

New York, NY
Jessica Merrill is a Bureau Editor for US Commercial Content for Informa’s pharmaceutical news publications, including “The Pink Sheet” and SCRIP. She has been covering the pharmaceutical industry as a journalist for more than 10 years, spanning the spectrum from R&D to regulatory to commercial. She was previously a reporter and editor for “The Pink Sheet” and “Pink Sheet” DAILY, specializing in business and commercial news, focusing largely on big pharma, M&A and business development, and the commercial landscape, including drug launches and market access. Before embarking on a career in healthcare journalism, she covered business news for the cosmetics industry and worked as a newspaper reporter.
Set Alert for Articles By Jessica Merrill

Latest From Jessica Merrill

Abuse-Deterrent Opioids: Where Are They Now?

The potential blockbuster category for abuse-deterrent opioids has fizzled. A few stalwarts are pushing on, but the return on investment for many drug manufacturers has been disappointing. Scrip tracked how opioids approved in the last eight years have performed.

Market Access Pricing Strategies

Alexion's Defensive Play Poised To Pay Off

The company's long-acting C5 complement inhibitor ALXN1210 demonstrated non-inferiority to Soliris in a Phase III trial, which should help the company defend against anticipated competition to its blockbuster franchise.

Blood & Coagulation Disorders Rare Diseases

From Pharma Insider To Payer: Witty To Lead United's Optum

Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.

Leadership Pharmacy Benefit Management

Praluent Pricing: Collaboration With ICER Sets A New Standard

Sanofi/Regeneron reveal plans to lower price of PCSK9 blocker Praluent to match ICER's updated recommendation, following assessment based on new outcomes data. Decision sparks debate across industry and raises questions about setting precedent on pricing for the future.

Pricing Debate Pricing Strategies

Cigna/Express Scripts: The End Of The Standalone PBM Era

The health insurer Cigna is poised to acquire the largest independent PBM in the US. With other consolidation throughout the sector, this signals sweeping changes to the way drug distribution is managed.
M & A Distribution

FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market

The FDA Commissioner called on payers to take steps to build the US biosimilar market and discouraged some early contracting schemes, calling them pay-for-delay tactics "dressed in the guise of rebates" in a notable speech at AHIP.

Biosimilars Pricing Debate
See All